CXCR4 and neuroendocrine neoplasm: This result is supported by another study that showed that in patients with neuroendocrine tumors, sunitinib treatment reduced the population of CD14+ monocytes expressing VEGFR-1 or CXCR4; however, the prognostic impact of this decrease was not reported [42].